Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition
American Journal of Hematology · 2024
DOI: 10.1002/ajh.27412 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift American Journal of Hematology, 2024. Verfasst von Alexander Röth und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Ge…. Hauptthemen laut MEDLINE: Hemoglobinuria, Paroxysmal, Antibodies, Monoclonal, Humanized, Complement Inactivating Agents. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Crovalimab is a novel C5 complement inhibitor that enables rapid and sustained C5 inhibition with subcutaneous, low‐volume self‐administration every 4 weeks. COMMODORE 2 (NCT04434092) is a global, randomized, open‐label, multicenter, phase 3 trial evaluating the non‐inferiority of crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria not previously treated with C5 inhibition. C5 inhibitor‐naive patients with lactate dehydrogenase (LDH) ≥2 × upper limit of normal (ULN) were randomized 2:1 to crovalimab or eculizumab. Co‐primary efficacy endpoints were proportion of patients with hemolysis control (centrally assessed LDH ≤1.5 × ULN) and proportion with transfusion avoidance. Secondary efficacy endpoints were proportions of patients with breakthrough hemolysis, stabilized hemoglobin, and change in FACIT‐Fatigue score. The primary treatment period was 24 weeks. Two hundred and four patients were randomized (135 crovalimab; 69 eculizumab). Crovalimab was non‐inferior to eculizumab in the co‐primary endpoints of hemolysis control (79.3% vs. 79.0%; odds ratio, 1.0 [95% CI, 0.6, 1.8]) and transfusion avoidance (65.7% vs. 68.1%; weighted difference, −2.8 [−15.7, 11.1]), and in the secondary efficacy endpoints of breakthrough hemolysis (10.4% vs. 14.5%; weighted difference, −3.9 [−14.8, 5.3]) and hemoglobin stabilization (63.4% vs. 60.9%; weighted difference, 2.2 [−11.4, 16.3]). A clinically meaningful improvement in FACIT‐Fatigue score occurred in both arms. Complete terminal complement activity inhibition was generally maintained with crovalimab. The safety profiles of crovalimab and eculizumab were similar with no meningococcal infections. Most patients who switched from eculizumab to crovalimab after the primary treatment period preferred crovalimab. These data demonstrate the positive benefit–risk profile of crovalimab.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
- Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, China.
- Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
- Department of Hematology, Affiliated Hospital of Nantong University, Jiangsu, China.
- Department of Hematology, Huashan Hospital, Fudan University, Shanghai, China.
- Faculty of Medicine Chiang Mai University, Chiang Mai, Thailand.
ORCID-Profile: Alexander Röth, Guangsheng He, Je-Hwan Lee, Roberta Demichelis-Gómez, Antonio Risitano
Zitieren
APA
Röth, A., He, G., Tong, H., Lin, Z., Wang, X., Chai-Adisaksopha, C., Lee, J. H., Brodsky, A., Hantaweepant, C., Dumagay, T. E., Demichelis-Gómez, R., Rojnuckarin, P., Sun, J., Höglund, M., Jang, J. H., Gaya, A., Silva, F., Obara, N., Kelly, R. J., …, & Han, B. (2024). Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition. American Journal of Hematology. https://doi.org/10.1002/ajh.27412
Vancouver
Röth A, He G, Tong H, Lin Z, Wang X, Chai-Adisaksopha C, et al. Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition. American Journal of Hematology. 2024. doi:10.1002/ajh.27412
BibTeX
@article{Rth2024,
author = {Röth, Alexander and He, Guangsheng and Tong, Hongyan and Lin, Zenghua and Wang, Xiaoqin and Chai-Adisaksopha, Chatree and Lee, Je-Hwan and Brodsky, Andres and Hantaweepant, Chattree and Dumagay, Teresita E and Demichelis-Gómez, Roberta and Rojnuckarin, Ponlapat and Sun, Jing and Höglund, Martin and Jang, Jun Ho and Gaya, Anna and Silva, Fernando and Obara, Naoshi and Kelly, Richard J and Beveridge, Leigh and Buatois, Simon and Chebon, Sammy and Gentile, Brittany and Lundberg, Pontus and Sreckovic, Sasha and Nishimura, Jun-Ichi and Risitano, Antonio and Han, Bing},
title = {Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition},
journal = {American Journal of Hematology},
year = {2024},
doi = {10.1002/ajh.27412}
}
EUVIMED